Unusual duplication mutation in a surface loop of human transthyretin leads to an aggressive drug-resistant amyloid disease

Elena S. Klimtchuk, Tatiana Prokaeva, Nicholas M. Frame, Hassan A. Abdullahi, Brian Spencer, Surendra Dasari, Haili Cui, John L. Berk, Paul J. Kurtin, Lawreen H. Connors, Olga Gursky

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Transthyretin (TTR) is a globular tetrameric transport protein in plasma. Nearly 140 single amino acid substitutions in TTR cause life-threatening amyloid disease. We report a one-of-a-kind pathological variant featuring a Glu51, Ser52 duplication mutation (Glu51_Ser52dup). The proband, heterozygous for the mutation, exhibited an unusually aggressive amyloidosis that was refractory to treatment with the small-molecule drug diflunisal. To understand the poor treatment response and expand therapeutic options, we explored the structure and stability of recombinant Glu51_Ser52dup. The duplication did not alter the protein secondary or tertiary structure but decreased the stability of the TTR monomer and tetramer. Diflunisal, which bound with near-micromolar affinity, partially restored tetramer stability. The duplication had no significant effect on the free energy and enthalpy of diflunisal binding, and hence on the drug–protein interactions. However, the duplication induced tryptic digestion of TTR at near-physiological conditions, releasing a C-terminal fragment 49–129 that formed amyloid fibrils under conditions in which the full-length protein did not. Such C-terminal fragments, along with the full-length TTR, comprise amyloid deposits in vivo. Bioinformatics and structural analyses suggested that increased disorder in the surface loop, which contains the Glu51_Ser52dup duplication, not only helped generate amyloid-forming fragments but also decreased structural protection in the amyloidogenic residue segment 25–34, promoting misfolding of the full-length protein. Our studies of a unique duplication mutation explain its diflunisal-resistant nature, identify misfolding pathways for amyloidogenic TTR variants, and provide therapeutic targets to inhibit amyloid fibril formation by variant TTR.

Original languageEnglish (US)
Pages (from-to)E6428-E6436
JournalProceedings of the National Academy of Sciences of the United States of America
Volume115
Issue number28
DOIs
StatePublished - Jul 10 2018

Fingerprint

Prealbumin
Amyloid
Diflunisal
Mutation
Pharmaceutical Preparations
Secondary Protein Structure
Amyloid Plaques
Amyloidosis
Amino Acid Substitution
Computational Biology
Tertiary Protein Structure
Digestion
Carrier Proteins
Proteins
Therapeutics

Keywords

  • Kinetic stability
  • Protein misfolding disease
  • Protein structural disorder
  • Proteolysis
  • Small-molecule drug binding

ASJC Scopus subject areas

  • General

Cite this

Unusual duplication mutation in a surface loop of human transthyretin leads to an aggressive drug-resistant amyloid disease. / Klimtchuk, Elena S.; Prokaeva, Tatiana; Frame, Nicholas M.; Abdullahi, Hassan A.; Spencer, Brian; Dasari, Surendra; Cui, Haili; Berk, John L.; Kurtin, Paul J.; Connors, Lawreen H.; Gursky, Olga.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 115, No. 28, 10.07.2018, p. E6428-E6436.

Research output: Contribution to journalArticle

Klimtchuk, Elena S. ; Prokaeva, Tatiana ; Frame, Nicholas M. ; Abdullahi, Hassan A. ; Spencer, Brian ; Dasari, Surendra ; Cui, Haili ; Berk, John L. ; Kurtin, Paul J. ; Connors, Lawreen H. ; Gursky, Olga. / Unusual duplication mutation in a surface loop of human transthyretin leads to an aggressive drug-resistant amyloid disease. In: Proceedings of the National Academy of Sciences of the United States of America. 2018 ; Vol. 115, No. 28. pp. E6428-E6436.
@article{5f99face0b0f433ebdde16236a455f19,
title = "Unusual duplication mutation in a surface loop of human transthyretin leads to an aggressive drug-resistant amyloid disease",
abstract = "Transthyretin (TTR) is a globular tetrameric transport protein in plasma. Nearly 140 single amino acid substitutions in TTR cause life-threatening amyloid disease. We report a one-of-a-kind pathological variant featuring a Glu51, Ser52 duplication mutation (Glu51_Ser52dup). The proband, heterozygous for the mutation, exhibited an unusually aggressive amyloidosis that was refractory to treatment with the small-molecule drug diflunisal. To understand the poor treatment response and expand therapeutic options, we explored the structure and stability of recombinant Glu51_Ser52dup. The duplication did not alter the protein secondary or tertiary structure but decreased the stability of the TTR monomer and tetramer. Diflunisal, which bound with near-micromolar affinity, partially restored tetramer stability. The duplication had no significant effect on the free energy and enthalpy of diflunisal binding, and hence on the drug–protein interactions. However, the duplication induced tryptic digestion of TTR at near-physiological conditions, releasing a C-terminal fragment 49–129 that formed amyloid fibrils under conditions in which the full-length protein did not. Such C-terminal fragments, along with the full-length TTR, comprise amyloid deposits in vivo. Bioinformatics and structural analyses suggested that increased disorder in the surface loop, which contains the Glu51_Ser52dup duplication, not only helped generate amyloid-forming fragments but also decreased structural protection in the amyloidogenic residue segment 25–34, promoting misfolding of the full-length protein. Our studies of a unique duplication mutation explain its diflunisal-resistant nature, identify misfolding pathways for amyloidogenic TTR variants, and provide therapeutic targets to inhibit amyloid fibril formation by variant TTR.",
keywords = "Kinetic stability, Protein misfolding disease, Protein structural disorder, Proteolysis, Small-molecule drug binding",
author = "Klimtchuk, {Elena S.} and Tatiana Prokaeva and Frame, {Nicholas M.} and Abdullahi, {Hassan A.} and Brian Spencer and Surendra Dasari and Haili Cui and Berk, {John L.} and Kurtin, {Paul J.} and Connors, {Lawreen H.} and Olga Gursky",
year = "2018",
month = "7",
day = "10",
doi = "10.1073/pnas.1802977115",
language = "English (US)",
volume = "115",
pages = "E6428--E6436",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "28",

}

TY - JOUR

T1 - Unusual duplication mutation in a surface loop of human transthyretin leads to an aggressive drug-resistant amyloid disease

AU - Klimtchuk, Elena S.

AU - Prokaeva, Tatiana

AU - Frame, Nicholas M.

AU - Abdullahi, Hassan A.

AU - Spencer, Brian

AU - Dasari, Surendra

AU - Cui, Haili

AU - Berk, John L.

AU - Kurtin, Paul J.

AU - Connors, Lawreen H.

AU - Gursky, Olga

PY - 2018/7/10

Y1 - 2018/7/10

N2 - Transthyretin (TTR) is a globular tetrameric transport protein in plasma. Nearly 140 single amino acid substitutions in TTR cause life-threatening amyloid disease. We report a one-of-a-kind pathological variant featuring a Glu51, Ser52 duplication mutation (Glu51_Ser52dup). The proband, heterozygous for the mutation, exhibited an unusually aggressive amyloidosis that was refractory to treatment with the small-molecule drug diflunisal. To understand the poor treatment response and expand therapeutic options, we explored the structure and stability of recombinant Glu51_Ser52dup. The duplication did not alter the protein secondary or tertiary structure but decreased the stability of the TTR monomer and tetramer. Diflunisal, which bound with near-micromolar affinity, partially restored tetramer stability. The duplication had no significant effect on the free energy and enthalpy of diflunisal binding, and hence on the drug–protein interactions. However, the duplication induced tryptic digestion of TTR at near-physiological conditions, releasing a C-terminal fragment 49–129 that formed amyloid fibrils under conditions in which the full-length protein did not. Such C-terminal fragments, along with the full-length TTR, comprise amyloid deposits in vivo. Bioinformatics and structural analyses suggested that increased disorder in the surface loop, which contains the Glu51_Ser52dup duplication, not only helped generate amyloid-forming fragments but also decreased structural protection in the amyloidogenic residue segment 25–34, promoting misfolding of the full-length protein. Our studies of a unique duplication mutation explain its diflunisal-resistant nature, identify misfolding pathways for amyloidogenic TTR variants, and provide therapeutic targets to inhibit amyloid fibril formation by variant TTR.

AB - Transthyretin (TTR) is a globular tetrameric transport protein in plasma. Nearly 140 single amino acid substitutions in TTR cause life-threatening amyloid disease. We report a one-of-a-kind pathological variant featuring a Glu51, Ser52 duplication mutation (Glu51_Ser52dup). The proband, heterozygous for the mutation, exhibited an unusually aggressive amyloidosis that was refractory to treatment with the small-molecule drug diflunisal. To understand the poor treatment response and expand therapeutic options, we explored the structure and stability of recombinant Glu51_Ser52dup. The duplication did not alter the protein secondary or tertiary structure but decreased the stability of the TTR monomer and tetramer. Diflunisal, which bound with near-micromolar affinity, partially restored tetramer stability. The duplication had no significant effect on the free energy and enthalpy of diflunisal binding, and hence on the drug–protein interactions. However, the duplication induced tryptic digestion of TTR at near-physiological conditions, releasing a C-terminal fragment 49–129 that formed amyloid fibrils under conditions in which the full-length protein did not. Such C-terminal fragments, along with the full-length TTR, comprise amyloid deposits in vivo. Bioinformatics and structural analyses suggested that increased disorder in the surface loop, which contains the Glu51_Ser52dup duplication, not only helped generate amyloid-forming fragments but also decreased structural protection in the amyloidogenic residue segment 25–34, promoting misfolding of the full-length protein. Our studies of a unique duplication mutation explain its diflunisal-resistant nature, identify misfolding pathways for amyloidogenic TTR variants, and provide therapeutic targets to inhibit amyloid fibril formation by variant TTR.

KW - Kinetic stability

KW - Protein misfolding disease

KW - Protein structural disorder

KW - Proteolysis

KW - Small-molecule drug binding

UR - http://www.scopus.com/inward/record.url?scp=85049641342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049641342&partnerID=8YFLogxK

U2 - 10.1073/pnas.1802977115

DO - 10.1073/pnas.1802977115

M3 - Article

VL - 115

SP - E6428-E6436

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 28

ER -